ReviewFrontiers in pharmacology2026
Therapeutic potential of growth hormone-releasing hormone analogues in cardiovascular and cerebrovascular diseases: mechanisms and preclinical evidence.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone-releasing hormone (GHRH) is a hypothalamic neuropeptide that stimulates growth hormone (GH) secretion from the pituitary gland, forming the central GHRH-GH-insulin-like growth factor-1 (IGF-1) endocrine axis. Beyond its classical endocrine function, GHRH and its receptors are widely expressed in extrapituitary tissues, where they regulate diverse physiological processes including cardiovascular function and neuroprotection. Preclinical studies demonstrate that synthetic GHRH analogues like MR-409 mitigate vascular calcification in diabetes, enhance cardiac repair post-myocardial infarction, and restore diastolic function in heart failure through calcium-handling modulation. In ischemic stroke models, MR-409 exhibits neuroprotective effects, reducing mortality and promoting neural regeneration. Studies performed in animal models have demonstrated the efficacy and therapeutic benefits of these compounds in diverse cardiomyopathies and ischemic stroke. Notably, these benefits occur independently of GH/IGF-1 signaling, highlighting their therapeutic potential for cardiovascular and cerebrovascular diseases. This narrative review synthesizes evidence from animal models, underscoring GHRH analogues as promising candidates for clinical translation. The articles included were identified through systematic searches in PubMed using keywords such as "GHRH analogues", "cardiovascular disease', and "ischemic stroke", with selection based on relevance to therapeutic applications and preclinical efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.